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Abstract
Background: Cardiac biomarkers are routinely obtained in the setting of suspected myocardial
ischemia and infarction. Evidence suggests these markers may correlate with functional and clinical
outcomes, but the strength of this correlation is unclear. The relationship between enzyme
measures of myocardial necrosis and left ventricular performance and adverse clinical outcomes
were explored.
Methods: Creatine kinase (CK) and CK-MB data were analyzed, as were left ventricular ejection
fraction (LVEF) by angiogram, and infarct size by single-photon emission computed tomography
(SPECT) imaging in patients in 2 trials: Prompt Reperfusion In Myocardial-infarction Evolution
(PRIME), and Efegatran and Streptokinase to Canalize Arteries Like Accelerated Tissue
plasminogen activator (ESCALAT). Both trials evaluated efegatran combined with thrombolysis for
treating acute ST-segment elevation myocardial infarction (STEMI).
Results:  Peak CK and CK area-under-the-curve (AUC) correlated significantly with SPECT-
determined infarct size 5 to 10 days after enrollment. Peak CK had a statistically significant
correlation with LVEF, but CK-AUC and LVEF correlation were less robust. Statistically significant
correlations exist between SPECT-determined infarct size and peak CK-MB and CK-MB AUC.
However, there was no correlation with LVEF for peak CK-MB and CK-MB AUC. The combined
outcome of congestive heart failure and death were significantly associated with CK AUC, CK-MB
AUC, peak CK, and peak CK-MB measurements.
Conclusion: Peak CK and CK-MB values and AUC calculations have significant correlation with
functional outcomes (LVEF- and SPECT-determined infarct size) and death or CHF outcomes in
the setting of STEMI. Cardiac biomarkers provide prognostic information and may serve as valid
endpoint measurements for phase II clinical trials.
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Background
There has been considerable interest in validating estab-
lished cardiac biomarkers as a mechanism for assessing
infarct size in clinical practice and as an endpoint in clin-
ical trials. Since assays for creatine kinase (CK) and CK-
MB became widely available in the 1970s, attempts have
been made to correlate the levels of these biomarkers with
outcomes and infarct size using kinetic models and curve-
fitting techniques [1-3]. Despite initial enthusiasm, these
models were later criticized because of their inability to
accurately predict the extent of myocardial necrosis [4-8].
Studies in animals [4,6,9,10] and humans [5,11,12] have
shown a significant correlation between CK and CK-MB-
derived estimations of myocardial damage after acute
myocardial infarction (MI) and the extent of damage at
necropsy, albeit in the era prior to reperfusion therapy.
Research has suggested that the quantity of cardiac mark-
ers released correlates with infarct size and with clinical
outcomes such as arrhythmias [13,14], heart failure
[13,15-17], and mortality [13,16,18,19] in the setting of
both ST-segment elevation myocardial infarction (STEMI)
and non-STEMI (NSTEMI). Since cardiac biomarkers are
relatively inexpensive to measure and are routinely used
in clinical practice, they are an attractive tool for easily
determining infarct size and gathering prognostic
information.
Little has been done to determine how the different meth-
ods used to assess infarct size in acute MI patients treated
with reperfusion therapy correlate. Improving our under-
standing of the methods used to measure infarct size and
clarifying the association between infarct size and out-
comes can be of tremendous value to clinical trials, partic-
ularly in the early evaluation of new therapies or
interventions.
The aims of the current analyses were to 1) determine
whether enzyme-determined infarct size would correlate
to the degree of infarction measured by single-photon
emission computed tomography (SPECT) imaging and to
left ventricular ejection fraction (LVEF) measured by LV
angiography, and 2) assess whether the amount of
enzyme released could be used to predict clinical out-
comes in patients treated with thrombolysis. For this anal-
ysis, data from the Efegatran and Streptokinase to
Canalize Arteries Like Accelerated Tissue plasminogen
activator (ESCALAT) [20] and Prompt Reperfusion In
Myocardial-infarction Evolution (PRIME) [21] trials were
used.
Methods
The trials
The ESCALAT trial has been published [20]. In brief,
ESCALAT was a randomized, dose-finding study in which
intravenous (IV) efegatran sulfate (in 1 of 4 doses) plus
streptokinase, or IV heparin plus accelerated tissue plas-
minogen activator (t-PA) was given to patients (N = 245)
presenting with acute STEMI. Trial participants were
between 21 and 75 years old, had ischemic chest pain for
≥ 30 minutes associated with ST-segment elevation of ≥
0.1 mV in 2 or more contiguous electrocardiographic
leads, and onset of symptoms within 12 hours of planned
treatment. The primary endpoint of infarct-related artery
patency was assessed by angiography at 90 minutes.
In the PRIME trial [21], patients (N = 336) with acute MI
were randomly assigned to accelerated t-PA and either IV
efegatran sulfate (in 1 of 5 doses) or IV heparin. In PRIME,
inclusion and exclusion criteria were similar to those for
ESCALAT [20,21]. The study protocol required coronary
angiography 90 minutes after start of t-PA therapy and
repeat angiography 5 to 7 days later.
SPECT and left ventricular (LV) functional assessments
SPECT quantification of infarct size was performed 5 to 10
days after randomization per the ESCALAT protocol.
SPECT images were evaluated in blinded fashion by a cen-
tral core laboratory (Georgetown University, Washington,
DC) using previously described methodologies [22].
In the PRIME trial, patients who did not have percutane-
ous coronary intervention or bypass surgery were to have
repeat coronary angiography 5 to 7 days after enrollment
or prior to hospital discharge, whichever occurred first. All
angiograms were reviewed by an independent evaluator,
blinded to treatment assignment, at a central core labora-
tory (Cleveland Clinic, Cleveland, Ohio). Angiograms
were assessed for vessel patency, Thrombolysis In Myocar-
dial Infarction (TIMI) flow grades, and LV function.
Biomarker determination of infarct size
In both the ESCALAT and PRIME trials, CK and CK-MB
levels were to be drawn at baseline (time of enrollment)
and at 6, 12, 24, 36, and 72 hours after enrollment. All
samples were analyzed at a central core laboratory (Uni-
versity of Maryland, College Park, MD), and the evaluator
was blinded to patient information. Cardiac biomarker
curves were then plot-fitted by the method proposed by
Vollmer and colleagues [23]. Area-under-the-curve (AUC)
and peak biomarker levels were derived for both CK and
CK-MB from these curve-fit data (Figure 1).
Clinical outcomes
Clinical outcomes of death or congestive heart failure
(CHF) that occurred during the index hospitalization
were reported by the investigator with standard data col-
lection tools without adjudication using standard
definitions.Current Controlled Trials in Cardiovascular Medicine 2005, 6:12 http://cvm.controlled-trials.com/content/6/1/12
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Statistical analysis
Statistical analyses were performed with SAS software
(version 6, SAS, Inc., Cary, North Carolina) on the UNIX
system. Continuous variables were summarized using
medians and interquartile ranges whereas categorical var-
iables were summarized as frequencies and percentages.
Patients from both trials were excluded from analyses if
they had a history of MI or no elevation of CK or CK-MB
due to confounding. Within the ESCALAT trial, after these
exclusions, the study size was 136 patients, representing
56% of the original study population. From the PRIME
trial, 165 patients were included in the analysis after
exclusions, accounting for 49% of the original trial popu-
lation (Figure 2).
Spearman rank correlations were used to determine asso-
ciations between the cardiac biomarker data and size of
infarct as measured by SPECT for the ESCALAT trial and
LVEF for the PRIME trial. Wilcoxon rank sum tests were
used to determine differences in continuous variables
between PRIME and ESCALAT.
Log normal plot of total CK data for a typical patient Figure 1
Log normal plot of total CK data for a typical patient. The connected points are from curve fitting, the solid circles are 
the actual measured points, and the solid triangles (along x-axis) are the residuals. In this case, the measured 8-hour point cor-
relates well with the calculated peak for the curve. CK: Creatine kinase, TCK: Total CK.Current Controlled Trials in Cardiovascular Medicine 2005, 6:12 http://cvm.controlled-trials.com/content/6/1/12
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Results
Baseline demographics
The baseline demographics were similar for the ESCALAT
and PRIME trial populations with respect to age, sex, race,
and history of smoking. None of the patients had a history
of MI as part of the inclusion criteria for this analysis.
Clinical outcomes
There were no significant differences in death or CHF dur-
ing the index hospitalization between the treatment
groups in either trial. There were also no statistical differ-
ences between the trials with respect to CK and CK-MB
data (Table 1); therefore, the trials were combined for fur-
ther analysis of enzyme release. Table 1 shows the infarct
size assessments by peak CK, peak CK-MB, CK-AUC, CK-
MB AUC, LVEF, and SPECT data.
Correlation of enzymes and SPECT
In ESCALAT, no differences in infarct size by SPECT imag-
ing, CK-AUC, or CK-MB AUC were observed between the
efegatran-plus-streptokinase- and heparin plus t-PA-
treated groups. Therefore, all treatment groups were com-
bined for these analyses. The median (25th, 75th) time to
SPECT was 6 days [5,16].
PRIME and ESCALAT study populations Figure 2
PRIME and ESCALAT study populations. CK: Creatine kinase, MI: Myocardial infarction. SPECT, Single-photon emis-
sion computed tomography.
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A scatter-plot of CK-MB AUC and SPECT infarct size is
shown in Figure 3. Statistically significant positive correla-
tions between the SPECT-determined infarct size and the
peak values for CK (r = 0.65, P < 0.0001) and CK-MB (r =
0.64, P < 0.0001) were observed. SPECT infarct size also
correlated with the AUC measurements for both CK (r =
0.63, P < 0.0001) and CK-MB (r = 0.58, P < 0.0001) (Table
2).
Correlation of enzymes and LVEF
In PRIME, repeat angiography with LVEF assessment was
repeated after a median (25th, 75th) of 5 days [4,6] from
thrombolysis. A statistically significant negative correla-
tion existed between LVEF measured at repeat angiogra-
phy and the peak levels of CK (r = -0.30, P = 0.035).
Borderline significant correlations were observed between
LVEF and CK-AUC (r = -0.28, P = 0.051). The negative cor-
relation between LVEF and peak CK-MB (r = -0.26, P =
0.06) as well as between LVEF and CK-MB AUC (r = -0.22,
P = 0.11) did not achieve statistical significance (Table 2).
Association between enzymes and outcomes
The total number of events in each trial is shown in Table
3. Figure 4 displays a graph of death/CHF and peak CK/
CK-AUC quintiles. Figure 5 is a similar graph of death/
CHF and peak CK-MB /CK-MB AUC quintiles. The Wil-
coxon rank sum test resulted in a statistically significant
association between death/CHF and peak CK (P = 0.007)
Table 1: ESCALAT and PRIME trials: assessments of myocardial damage
ESCALAT n = 136 PRIME n = 165 P value
Peak CK
n1 2 7 1 5 8
Median (25th, 75th) 1790.0 (682, 2580) 1730.0 (931, 2850) 0.6718
Peak CK-MB
n1 2 9 1 6 1
Median (25th, 75th) 209 (82, 340) 207 (101, 362) 0.6239
CK-MB AUC
n1 2 9 1 6 1
Median (25th, 75th) 3887.0 (1617, 6099) 3891.0 (2035, 6746) 0.1588
CK AUC
n1 2 7 1 5 8
Median (25th, 75th) 50960 (22950, 79620) 51295 (29930, 87390) 0.1801
LVEF (%)
nn / a 5 2
Median (25th, 75th) n/a 58.0 (50, 66) n/a
SPECT (% infarcted)
n1 2 2 n / a
Median (25th, 75th) 13.0 (4, 24) n/a n/a
P values obtained using Wilcoxon rank sum test.
AUC: Area-under-the-curve, CK: creatine kinase, ESCALAT: Efegatran and Streptokinase to Canalize Arteries Like Accelerated Tissue 
plasminogen activator, LVEF: left ventricular ejection fraction, PRIME: Prompt Reperfusion In Myocardial infarction Evolution, SPECT: single-
photon emission computed tomography
Table 2: ESCALAT and PRIME trials: correlations of enzymes with LVEF- and SPECT-determined infarct size
Peak CK Peak CK-MB CK AUC CK-MB AUC
LVEF r = -0.30 r = -0.26 r = -0.28 r = -0.22
P = 0.0354 P = 0.0599 P = 0.0508 P = 0.1117
n = 50 n = 51 n = 50 n = 51
SPECT r = 0.65 r = 0.64 r = 0.63 r = 0.58
P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
n = 115 n = 116 n = 115 n = 116
AUC: Area-under-the-curve; CK: creatine kinase, ESCALAT: Efegatran and Streptokinase to Canalize Arteries Like Accelerated Tissue 
plasminogen activator, LVEF: left ventricular ejection fraction, PRIME: Prompt Reperfusion In Myocardial infarction Evolution, SPECT: single-
photon emission computed tomographyCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:12 http://cvm.controlled-trials.com/content/6/1/12
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and AUC (P = 0.001) measurements; there was also an
association between death/CHF and peak CK-MB (P =
0.021) and AUC (P = 0.005) measurements.
Discussion
This study showed a significant correlation between inf-
arct size as assessed by SPECT and infarct size as
determined by CK and CK-MB release using AUC or peak
values. Weaker correlations were observed between infarct
size measured by cardiac biomarker assessments and LVEF
determined by angiography. Patients with larger release of
CK or CK-MB had an increased risk of death and/or CHF.
These findings are consistent with earlier studies [12,24-
33] that have also examined the correlation between CK
and CK-MB and SPECT-determined infarct size. However,
the majority of these analyses were done in the era prior
to reperfusion therapy with fibrinolytic therapy or percu-
taneous coronary intervention. Therefore, the current
analysis is important for trials being planned in the STE
AMI population with contemporary therapies.
Attempts have been made to correlate CK- and CK-MB-
based infarct measurements with LV function, with con-
flicting results. EF has been variably correlated to CK-MB
Natural log of peak CK-MB and percent infarcted myocardium (SPECT) Figure 3
Natural log of peak CK-MB and percent infarcted myocardium (SPECT). AUC: Area-under-the-curve, CK: Creat-
ine kinase, LN: log normal, SPECT: Single-photon emission computed tomography.
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AUC [17,34], peak CK-MB [17,35], CK AUC [15,36], and
peak CK [36] in several angiographic studies, as well as in
1 radionucleotide study involving patient numbers
similar to those in our study. Although the data confirm a
significant association between LVEF determined by angi-
ography and peak CK, the Spearman coefficient revealed
only a weak relationship. This may have been in part due
to small sample sizes.
The relatively poor correlation noted here between angio-
graphic and enzymatic methods of infarct sizing might be
due to post-infarct stunning, leading to an artifactually
low LVEF; earlier clinically or electrocardiographically
silent MIs contributing to LV dysfunction attributed to the
index event; site of infarct (inferior vs. anterior); and the
degree of right ventricular involvement. There also
appears to be wide variability in the published Spearman
coefficients on enzyme/LVEF correlations, with the cur-
rent data falling at the lower end of the previously pub-
lished ranges. These discrepant results might be explained
by a number of factors, including variations in enzyme
curve measurements; inter- and intra-study variability of
LVEF measurements; timing of catheterization relative to
MI; differences in treatment allotments; the year of study,
which has implications for the availability of reperfusion
and improvements in coronary care; and publication bias,
with nonsignificant or weak association preferentially not
being reported in the literature.
The ability of cardiac enzymes to predict clinical out-
comes would enhance confidence in the use of this
assessment in phase II clinical trials but would not
exclude the need to conduct definitive trials designed to
assess clinical outcomes directly. An early study of
Incidence of new CHF and death by CK-AUC and peak CK measurements, according to quintiles Figure 4
Incidence of new CHF and death by CK-AUC and peak CK measurements, according to quintiles. AUC: Area-
under-the-curve, CHF: congestive heart failure, CK: Creatine kinase.
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patients presenting with acute MI prior to the era of wide-
spread revascularization showed a correlation between
peak CK and CK-AUC and arrhythmias, pulmonary
edema, and higher pulmonary artery wedge pressure [37].
Subsequently, in the Global Utilization of Streptokinase
and Tissue plasminogen activator for Occluded coronary
arteries (GUSTO-I) enzyme substudy [38], a 12% decrease
in infarct size (as measured by α-hydroxybutyrate dehy-
drogenase), with t-PA (compared with streptokinase) cor-
responded to the 14% relative mortality reduction in the
trial overall [39]. More recently, analysis from the Throm-
bolysis and Angioplasty in Myocardial Infarction (TAMI-
7) trial of accelerated alteplase in patients presenting with
ST-segment elevations showed a clear correlation between
CK-MB peak and AUC values and development of CHF
and a composite of CHF and death [17]. Similarly, data
from the Platelet glycoprotein IIb/IIIa in Unstable angina:
Receptor Suppression Using Integrilin Therapy (PUR-
SUIT) trial showed a graded risk of death at 30 days and 6
months based on peak CK and CK-MB in NSTEMI [19]. In
keeping with prior studies, we were able to demonstrate a
graded risk of adverse cardiovascular outcomes (defined
as new CHF and death) with a statistically significant
increase of events in patients in higher quintiles of peak
and AUC measurements for both CK and CK-MB.
The strengths of the present study are that the data were
collected in the context of 2 randomized, controlled trials
Incidence of new CHF and death by CK-MB AUC and peak CK-MB measurements, according to quintiles Figure 5
Incidence of new CHF and death by CK-MB AUC and peak CK-MB measurements, according to quintiles. 
AUC: Area-under-the-curve, CHF: congestive heart failure, CK: Creatine kinase.
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Table 3: ESCALAT and PRIME trials: clinical outcomes
ESCALAT n = 136 PRIME n = 165
Death 2 (1.5) 5 (3.0)
New CHF Not collected 21 (12.7)
Death/new CHF 2 (1.5) 22 (13.3)
Values are n (%)
CHF: Congestive heart failure, ESCALAT: Efegatran and 
Streptokinase to Canalize Arteries Like Accelerated Tissue 
plasminogen activator, PRIME: Prompt Reperfusion In Myocardial 
infarction EvolutionCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:12 http://cvm.controlled-trials.com/content/6/1/12
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with strict adherence to serial biomarker assessments,
analyses by a central core laboratory, and sophisticated
curve-fitting techniques. Most of the noted previous stud-
ies used the modified formula proposed by Roberts et al
[2] in 1975, to calculate the cumulative enzyme release.
For this study, in contrast, a log normal function was used
to correlate AUC values and to curve-fit in order to find
peak enzyme levels; more recent data show that the log
normal function best approximates the true enzyme
release curve and peak values [23]. This method is easy to
use and requires less sampling than other methods of
curve fitting. The log normal function has obvious
advantages over older methods and a clear role in data
collection for prospective studies of infarction.
Limitations
Several weaknesses should be acknowledged. Sample
sizes from the 2 trials were relatively small. The ventricu-
lographic and scintigraphic data were incomplete, which
may have implications if the missing data were signifi-
cantly different from that reported here. Also, to more
accurately assess the damage done by the index infarction,
this analysis included only patients presenting with their
first MI. This factor may affect the generalizability of the
results. Although plot-fitting appears to be the most accu-
rate method of determining enzyme peaks and integrating
areas given current routine practices in measuring cardiac
markers, it is possible that the sampling frequency used
misrepresented the true nature of the enzyme curves.
Finally, cardiac biomarkers, though useful, still represent
surrogate measurements of clinical outcomes and need to
be used with caution in the evaluation of new therapies,
because a new treatment that has had no effect on a surro-
gate measurement (such as CK or CK-MB) might still have
an important treatment effect.
Given the small sample size, we were not able to rigor-
ously assess the potential impact of infarct location on the
relationships observed. The contribution of right ventricu-
lar infarct to CK-MB release and the correlation of this
release to assessment of left ventricular function could
confound these findings.
Implications
Given their affordability and routine availability, cardiac
biomarkers remain an attractive tool for measuring
myocardial damage and determining prognosis. Cardiac
enzyme markers continue to be used as endpoints in
clinical trials, such as the Complement And ReDuction of
INfarct size after Angioplasty or Lytics (CARDINAL) pro-
gram [40,41] and the Limitation of Myocardial Infarction
Following Thrombolysis in Acute Myocardial Infarction
(LIMIT AMI) [42] trials. These results support the use of
biomarker-based infarct sizing in the evaluation of thera-
peutics, treatment effects, and outcomes.
An attractive alternative in early drug development is to
continue to combine a variety of measures of efficacy,
such as cardiac enzymes, ECG analysis, SPECT, and angi-
ography, to develop a "biomarker array." If multiple vali-
dated and significant prespecified outcomes are analyzed
in the context of phase II clinical research, fewer patients
would potentially need to be enrolled to discern differ-
ences in treatment effects between trial arms. This analysis
substantiates the concept that routine cardiac markers can
predict infarct size and clinical outcomes and may there-
fore act as a valid endpoint in phase II trials of acute MI
therapy.
Conclusion
Serial cardiac biomarker assessment and curve-fitting
techniques can be used to determine infarct size with sta-
tistically significant correlation to SPECT imaging. Weaker
correlations were observed with LVEF by angiography.
Death and CHF outcomes were associated with larger inf-
arct size as determined by biomarkers. These data support
the use of biomarker-determined infarct size as a potential
endpoint in phase II clinical trials.
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